G
Gain Therapeutics D
D
GANX
2.57000
USD
-0.07
(-2.65%)
Market Closed
Volume
0
EPS
-1
Div Yield
-
P/E
-4
Market Cap
98,847,558
Title: Gain Therapeutics
Sector: Healthcare
Industry: Biotechnology
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates inSwitzerland, Spain, the United States, and Australia.